Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | DGAT1 | O75907 | 9/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13009439 | 0.90 | IDO1 (0.47) | IDO1DGAT1HDAC3HDAC11HDAC8 | |
| SCHEMBL3543032 | 0.90 | IDO1 (0.50) | IDO1DGAT1HDAC3HDAC11HDAC8 | |
| SCHEMBL3543034 | 0.90 | IDO1 (0.50) | IDO1DGAT1HDAC3HDAC11HDAC8 | |
| SCHEMBL13008026 | 0.87 | KDM4E (0.46) | IDO1DGAT1HDAC3HDAC11HDAC8 | |
| SCHEMBL14199019 | 0.87 | KDM4E (0.46) | IDO1DGAT1HDAC3HDAC11HDAC8 | |
| SCHEMBL13061618 | 0.86 | IDO1 (0.44) | IDO1DGAT1HDAC3HDAC11HDAC8 | |
| SCHEMBL1399684 | 0.82 | HDAC3 (0.40) | IDO1HDAC3HDAC11HDAC8HDAC6 | |
| SCHEMBL13755353 | 0.82 | HDAC3 (0.40) | IDO1DGAT1HDAC3HDAC11HDAC8 | |
| SCHEMBL1399682 | 0.82 | HDAC3 (0.40) | IDO1HDAC3HDAC11HDAC8HDAC6 | |
| SCHEMBL13009528 | 0.82 | DGAT1 (0.40) | IDO1DGAT1EPHX2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2035417-B1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATEMNT OF DIABETES | ASTRAZENECA AB (SE) | 2011-03-02 | — | — | EP | disclosed |
| EP-2035417-B1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATEMNT OF DIABETES | ASTRAZENECA AB (SE) | 2011-03-02 | — | — | EP | disclosed |
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | US | disclosed |
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | US | disclosed |
| US-7795283-B2 | Oxadiazole derivative as DGAT inhibitors | ASTRAZENECA AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-7795283-B2 | Oxadiazole derivative as DGAT inhibitors | ASTRAZENECA AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-20090215779-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | US | disclosed |
| US-20090215779-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | US | disclosed |
| US-20090215779-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | US | disclosed |
| US-20090197926-A1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-08-06 | — | — | US | disclosed |
| US-20090197926-A1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-08-06 | — | — | US | disclosed |
| US-20090197926-A1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-08-06 | — | — | US | disclosed |
| EP-2035417-A1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATEMNT OF DIABETES | AstraZeneca AB (SE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2008129319-A1 | SALTS OF OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| WO-2007144571-A1 | CRYSTALLINE FORM OF (TRANS-4- [ ( { 5- [ (3, 4 -DI FLUOROPHENYL) AMINO] -1,3, 4-OXADIAZOL-2-YL}CARBONYL) AMINO] PH ENYL } CYCLOHEXYL) ACETIC ACID | ASTRAZENECA AB (SE) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007141517-A1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATEMNT OF DIABETES | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007141517-A1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATEMNT OF DIABETES | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | DGAT1, DGAT2, GPR119 | IDO1 2690/4885DGAT1 1/4885HDAC3 256/4885 |
| US-20090197926-A1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATMENT OF DIABETES | DGAT1, ACAT1, DGAT2 | IDO1 2046/4885DGAT1 1/4885HDAC3 71/4885 |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | DGAT1, DGAT2, GPR119 | IDO1 2567/4885DGAT1 1/4885HDAC3 187/4885 |
| US-20090215779-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | DGAT2, GPR119, DGAT1 | IDO1 2912/4885DGAT1 3/4885HDAC3 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.